vimarsana.com

Latest Breaking News On - Onzetra xsail - Page 1 : vimarsana.com

MVM Partners LLC Invests $18 77 Million in OptiNose, Inc (NASDAQ:OPTN)

MVM Partners LLC acquired a new position in OptiNose, Inc. (NASDAQ:OPTN – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,605,263 shares of the company’s stock, valued at approximately $18,768,000. OptiNose comprises approximately 10.9% of MVM Partners […]

OptiNose (NASDAQ:OPTN) Given Buy Rating at HC Wainwright

OptiNose (NASDAQ:OPTN) Given Buy Rating at HC Wainwright
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

OptiNose s (OPTN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of OptiNose (NASDAQ:OPTN – Free Report) in a research note published on Monday, Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for OptiNose’s Q1 2024 earnings at ($0.11) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 […]

OptiNose s (OPTN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of OptiNose (NASDAQ:OPTN – Free Report) in a research note published on Monday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for OptiNose’s Q1 2024 earnings at ($0.11) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings […]

OptiNose (NASDAQ:OPTN) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of OptiNose (NASDAQ:OPTN – Get Free Report) in a report issued on Monday, Briefing.com reports. The firm set a “buy” rating and a $5.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 163.85% from the company’s previous close. OptiNose Stock Up 1.9 […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.